Recursion Pharma gains on completing Nvidia-backed supercomputer BioHive-2
13/05/2024 13:59
** Shares of drug developer Recursion Pharmaceuticals
RXRX.O rise 5% to $9.02 in premarket trading
** RXRX announces completion of Nvidia-powered NVDA.O
supercomputer BioHive-2, which the company says is the largest
supercomputer in pharmaceutical industry
** BioHive-2 is four times faster than RXRX's original
supercomputer BioHive-1 in benchmark performance tests
** RXRX uses AI to discover new drug candidates
** Cathie Wood-led ARK Invest bought 526,148 RXRX shares on
Friday
** As of last close, RXRX down 12.8% YTD vs 8.9% rise in
tech-heavy Nasdaq .IXIC
(Reporting by Nikhil Sharma in Bengaluru)
((Nikhil.Sharma@thomsonreuters.com))
Recent news on Recursion Pharmaceuticals
See all newsBrief: Tempus And Recursion Extend Existing Data License Agreement And Enter New License Agreement For Recursion’S RNA Foundation Model
Brief: Recursion Pharmaceuticals Enters Amendment To Master Agreement With Tempus On Sept 15, 2026 - SEC Filing
Recursion Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Recursion Pharmaceuticals Q2 revenue misses estimates, cuts 2026 expense outlook
Brief: Recursion Pharmaceuticals Q2 Operating Revenue USD 7.303 Million Vs. IBES Estimate USD 11.9 Million